Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928965 | 0.84 | GRM5 (0.74) | GRM5 | |
| SCHEMBL6918313 | 0.81 | GRM5 (0.60) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 | |
| SCHEMBL6928710 | 0.79 | GRM5 (0.80) | GRM5CYP3A4 | |
| SCHEMBL6928562 | 0.79 | GRM5 (1.00) | GRM5CYP1A2CYP2C9 | |
| SCHEMBL6929336 | 0.79 | GRM5 (0.61) | GRM5 | |
| SCHEMBL6929666 | 0.77 | GRM5 (1.00) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 | |
| SCHEMBL6918286 | 0.77 | GRM5 (0.67) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 | |
| SCHEMBL6929658 | 0.75 | GRM5 (1.00) | GRM5CYP3A4 | |
| SCHEMBL6918401 | 0.74 | GRM5 (0.61) | GRM5CYP3A4 | |
| SCHEMBL30761111 | 0.72 | GRM5 (0.55) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477629-B1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | UNIV VANDERBILT (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| WO-2011035186-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885CYP1A2 3825/4885CYP2C9 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.